Key Highlights

  • Silence Therapeutics (NASDAQ:SLN) rose 77.40% over one month in published market data as of October 28, 2026, after Merck KGaA agreed on October 19, 2026 to buy the company for USD 20 per American depositary share in cash.
  • The USD 20 price equals USD 6.6667 per ordinary share, since each ADS represents three shares, and values the company at about USD 1.3 billion, a premium of 130% to the prior price.
  • Completion is expected in the first quarter of 2027, subject to Silence shareholder approval, sanction by the High Court of Justice of England and Wales and other closing conditions for Silence Therapeutics (NASDAQ:SLN).
  • The latest quote of USD 19.75 sits about 1.3% below the offer, simple arithmetic on two published numbers, which suggests investors expect the deal to close.

The Merck KGaA Offer

Silence Therapeutics, an RNA interference company, and Merck KGaA announced the transaction on October 19, 2026 in separate statements. Merck KGaA will pay USD 20 in cash for each ADS, an all-cash deal valued at about USD 1.3 billion. On the day Silence Therapeutics (NASDAQ:SLN) reportedly more than doubled and closed at USD 19.58, up 125.58%, about 2% below the offer. Chairman Iain Ross tied the deal to potentially best-in-class Phase 2 polycythemia vera data for divesiran, which passes to the German group. Chief Executive Kai Beckmann said the purchase strengthens its position in targeted specialty and rare diseases. Merck KGaA is based in Germany and has no US listing, so no ticker applies to the buyer.

How the Deal Works

Three approvals are needed: Silence shareholders, the High Court of Justice of England and Wales, and regulators. Because the buyer pays cash, the stock behaves like a fixed-income instrument anchored at the offer. A spread of about 1.3% between USD 19.75 and USD 20 compensates holders for time and risk and narrows as closing approaches. Divesiran is the key asset: a Phase 3 program would need Merck KGaA's scale, which is the stated rationale. Hedge fund positions reportedly rose from 13 funds in the first quarter to 24 in the second, and unusually large options volume was reported on October 20. The German group's purchase of SpringWorks Therapeutics last year shows its appetite for external innovation, according to its chief executive.

Risks and Next Steps

Deal risks include a failed shareholder vote, court delays, regulatory review and a material change in divesiran data. If the transaction collapsed, the stock could fall toward its pre-offer level, since USD 20 is a 130% premium to the earlier price. Upside above USD 20 would need a competing bid, and none is reported. The monthly gain of 77.40% and the one-day jump of 125.58% differ because they are measured from different start dates. Silence Therapeutics (NASDAQ:SLN) holders should watch the shareholder meeting timetable and any regulatory filings, which will set the path to closing. Closing is a process, not a single event, because shareholders must vote and the court must sanction the transaction before cash is paid.

Where Things Stand

Silence Therapeutics (NASDAQ:SLN) rose 77.40% because Merck KGaA agreed on October 19, 2026 to buy it for USD 20 per ADS in cash, a 130% premium, and the stock now trades about 1.3% under the offer. This is a takeover move, not a fundamental re-rating, so further upside depends on a rival bidder. The balance of evidence points to completion in the first quarter of 2027, with shareholder approval and court sanction the remaining gates and the meeting schedule the next catalyst.